Susan Chi, MD
Clinical Director, Brain Tumor Center; Attending Physician, Dana-Farber/Boston Children’s Blood Disorders CenterAttending Physician, Dana-Farber/Boston Children’s Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Image
Susan Chi, MD
Clinical Director, Brain Tumor Center; Attending Physician, Dana-Farber/Boston Children’s Blood Disorders CenterAttending Physician, Dana-Farber/Boston Children’s Blood Disorders Center
Associate Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Princeton University
1990
Princeton
NJ
Medical School
Mt. Sinai School of Medicine
1994
New York
NY
Residency
Pediatrics
Yale-New Haven Children's Hospital
1998
New Haven
CT
Fellowship
Memorial Sloan-Kettering Cancer Center
2001
New York
NY
Fellowship
New York University Medical Center
2002
New York
NY
Publications
Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. View Abstract
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions. View Abstract
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. View Abstract
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity. View Abstract
Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional Experience. View Abstract
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. View Abstract
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. View Abstract
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. View Abstract
Clinical utility of DNA methylation profiling for choroid plexus tumors. View Abstract
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. View Abstract
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. View Abstract
Cancer survivorship programs at the Dana-Farber Cancer Institute. View Abstract
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. View Abstract
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial. View Abstract
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. View Abstract
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. View Abstract
ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. View Abstract
Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. View Abstract
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT). View Abstract
p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition. View Abstract
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. View Abstract
PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors. View Abstract
An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry. View Abstract
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. View Abstract
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. View Abstract
DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. View Abstract
Pearls & Oy-sters: Pivoting Treatment Regimens of Pediatric Atypical Teratoid Rhabdoid Tumors to Optimize Care in Adult ATRT: A Case Report. View Abstract
Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma. View Abstract
The challenges in treating embryonal tumors with multilayered rosettes (ETMR) and other infant brain tumors. View Abstract
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. View Abstract
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
Outcomes after first relapse of childhood intracranial ependymoma. View Abstract
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. View Abstract
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. View Abstract
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. View Abstract
A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes. View Abstract
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. View Abstract
Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. View Abstract
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. View Abstract
Mechanisms and therapeutic implications of hypermutation in gliomas. View Abstract
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. View Abstract
Increasing value of autopsies in patients with brain tumors in the molecular era. View Abstract
Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. View Abstract
Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. View Abstract
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. View Abstract
A Central Role of Radiation Therapy in Central Nervous System Germinoma. View Abstract
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. View Abstract
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. View Abstract
Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study. View Abstract
Improvement of hereditary palmoplantar keratoderma with oral trametinib. View Abstract
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. View Abstract
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. View Abstract
Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. View Abstract
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. View Abstract
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. View Abstract
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. View Abstract
Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. View Abstract
Pediatric oncology enters an era of precision medicine. View Abstract
Pediatric malignant germ cell tumors: A comparison of the neuro-oncology and solid tumor experience. View Abstract
Central Versus Extraventricular Neurocytoma in Children: A Clinicopathologic Comparison and Review of the Literature. View Abstract
Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. View Abstract
Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. View Abstract
Building a new process: Nursing verification of pediatric oral chemotherapy. View Abstract
Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. View Abstract
Myxopapillary ependymomas in children: imaging, treatment and outcomes. View Abstract
Classification of treatment-related mortality in children with cancer: a systematic assessment. View Abstract
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. View Abstract
Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. View Abstract
Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. View Abstract
Phase I individual dose titration trial of the human corticotropin-releasing factor (hcrf), corticorelin acetate injection (xerecept) in pediatric patients with peritumoral edema of the brain. View Abstract
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. View Abstract
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. View Abstract
Predictors of neoplastic disease in children with isolated pituitary stalk thickening. View Abstract
Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. View Abstract
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. View Abstract
Sleep dysfunction in long term survivors of craniopharyngioma. View Abstract
Brain tumors in children. View Abstract
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. View Abstract
Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. View Abstract
Germinoma with malignant transformation to nongerminomatous germ cell tumor. View Abstract
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. View Abstract
Biological modification strategies following marrow ablative, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (AHSCR) for pediatric brain tumors. View Abstract
Introduction to a special issue on pediatric neuro-oncology. View Abstract
A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. View Abstract
Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. View Abstract
Pediatric Neuro-Oncology: Back to the Basics View Abstract
Tumors of the Brain and Spinal Cord View Abstract
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. View Abstract
Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. View Abstract
Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. View Abstract
Results from a single-arm, multi-institutional Phase II study Of multi-agent intrathecal and systemic Cchemotherapy with age- and risk-adapted radiation therapy for children with newly diagnosed CNS Atypical Teratoid/Rhabdoid Tumor View Abstract
Long-term medical, psychologicak and educational isues in pediatric low-grade gliomas treated with surgery only View Abstract
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. View Abstract
Moyamoya following cranial irradiation for primary brain tumors in children. View Abstract
Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: a final update on “Head Start” induction chemotherapy intensified with high-dose methotrexate View Abstract
Pineoblastoma in the pediatric population: Review of a single institution’s experience View Abstract
Glomerular filtration rate in comparison to serum creatinine and audiologic results in predicting toxicity in pediatric patients receiving vincristine and carboplatin View Abstract
Does histologic grade correlate with clinical outcome in pediatric intracranial ependymoma? View Abstract
Supratentorial primitive neuroectodermal tumors: Final outcome for children enrolled on Head Start I and II View Abstract
Oligodendroglial lineage marker expression in ependymal tumors View Abstract
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. View Abstract
Transverse myelitis after therapy for primitive neuroectodermal tumors. View Abstract
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. View Abstract
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. View Abstract
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. View Abstract
The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. View Abstract
Pediatric Neuro-Oncology Program Fellows Manual View Abstract
Expression of SSX-2 and SSX-4 genes in neuroblastoma. View Abstract
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. View Abstract
Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. View Abstract